clinical trial · NCT07483099
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
Eli Lilly and Company·phase2·not yet recruiting·n = 60
Crohn DiseaseLY4395089Mirikizumab - Intravenous (IV)Mirikizumab - Subcutaneous (SC)
brief summary
The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely active Crohn's disease (CD). This study is part of the IIBD master protocol and will last approximately 62 weeks.
started
Apr 1, 2026
primary completion
Jun 1, 2027
completion
Mar 1, 2028
last updated
Apr 21, 2026
official title
A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/Mirikizumab Co-administration Compared With Mirikizumab in Adults With Moderately to Severely Active Crohn's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol